{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:35:51Z","timestamp":1767339351957},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.nbd.2010.02.009","type":"journal-article","created":{"date-parts":[[2010,3,8]],"date-time":"2010-03-08T05:49:01Z","timestamp":1268027341000},"page":"492-494","source":"Crossref","is-referenced-by-count":6,"title":["Thinking outside the box about COX-1 in Alzheimer's disease"],"prefix":"10.1016","volume":"38","author":[{"given":"Sally A.","family":"Frautschy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2010.02.009_bib1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0306-4522(02)00907-7","article-title":"In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile","volume":"117","author":"Agdeppa","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2010.02.009_bib2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2010.02.009_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/156720508783884602","article-title":"Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial","volume":"5","author":"Aisen","year":"2008","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.nbd.2010.02.009_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer's disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2010.02.009_bib5","doi-asserted-by":"crossref","unstructured":"Choi, J.K., et al., 2009. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp. Neurol. PMID 19679126. doi:10.1016\/j.expneurol.2009.07.032.","DOI":"10.1016\/j.expneurol.2009.07.032"},{"key":"10.1016\/j.nbd.2010.02.009_bib6","doi-asserted-by":"crossref","unstructured":"Coma, M., et al., 2010. Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. (Electronic publication ahead of print). PMID: 20149872. doi:10.1016\/j.nbd.2010.01.019.","DOI":"10.1016\/j.nbd.2010.01.019"},{"key":"10.1016\/j.nbd.2010.02.009_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/WAD.0b013e3181611024","article-title":"A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study","volume":"22","author":"Gomez-Isla","year":"2008","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.nbd.2010.02.009_bib8","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/brain\/awh452","article-title":"Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice","volume":"128","author":"Heneka","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2010.02.009_bib9","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2174\/138161208784480171","article-title":"Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology","volume":"14","author":"Hoozemans","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.nbd.2010.02.009_bib34","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1369\/jhc.2008.951855","article-title":"Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease","volume":"56","author":"Ikonomovic","year":"2008","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.nbd.2010.02.009_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2010.02.009_bib11","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1523\/JNEUROSCI.22-06-02246.2002","article-title":"Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice","volume":"22","author":"Jantzen","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.02.009_bib12","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/ndt\/gfp004","article-title":"Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo","volume":"24","author":"Jespersen","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.nbd.2010.02.009_bib13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/brain\/awn008","article-title":"Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity","volume":"131","author":"Kotilinek","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2010.02.009_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2202-8-54","article-title":"Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice","volume":"8","author":"Kukar","year":"2007","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.nbd.2010.02.009_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.NT.0000361424.09130.9e","article-title":"In follow-up analysis of clinical trial, NSAIDs seem to preserve cognitive function in patients with healthy brains","volume":"9","author":"Laino","year":"2009","journal-title":"Neurol. Today"},{"issue":"15","key":"10.1016\/j.nbd.2010.02.009_bib16","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1523\/JNEUROSCI.20-15-05709.2000","article-title":"Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease","volume":"20","author":"Lim","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.02.009_bib17","doi-asserted-by":"crossref","first-page":"983-981","DOI":"10.1016\/S0197-4580(01)00299-8","article-title":"Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice","volume":"22","author":"Lim","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2010.02.009_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/JAD-2010-1219","article-title":"Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy","volume":"19","author":"McGeer","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2010.02.009_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.brainres.2008.01.095","article-title":"Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice","volume":"1207","author":"McKee","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2010.02.009_bib20","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/sj.npp.1300668","article-title":"Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models","volume":"30","author":"Morihara","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nbd.2010.02.009_bib21","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1046\/j.1471-4159.1996.66062532.x","article-title":"Interleukin-1 beta induces prostaglandin G\/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures","volume":"66","author":"O'Banion","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2010.02.009_bib22","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1471-4159.2005.03150.x","article-title":"Cyclo-oxygenase-1 and -2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N-methyl-d-aspartate receptors in rat hippocampus","volume":"93","author":"Pepicelli","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2010.02.009_bib23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0006-8993(03)02248-0","article-title":"Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats","volume":"968","author":"Rall","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2010.02.009_bib24","doi-asserted-by":"crossref","first-page":"81s","DOI":"10.18433\/J3T886","article-title":"Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond","volume":"11","author":"Rao","year":"2008","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.nbd.2010.02.009_bib25","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1212\/WNL.43.8.1609","article-title":"Clinical trial of indomethacin in Alzheimer's disease","volume":"43","author":"Rogers","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2010.02.009_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1212\/WNL.53.1.197","article-title":"A double-blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer's disease","volume":"53","author":"Scharf","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2010.02.009_bib27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/JGP.0b013e31818cd3a4","article-title":"Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study","volume":"16","author":"Small","year":"2008","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.nbd.2010.02.009_bib28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00401-009-0556-6","article-title":"Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease","volume":"118","author":"Streit","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2010.02.009_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejphar.2008.11.058","article-title":"Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis","volume":"603","author":"Tanaka","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nbd.2010.02.009_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.expneurol.2008.09.003","article-title":"Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation","volume":"215","author":"Walker","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2010.02.009_bib31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity","volume":"414","author":"Weggen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2010.02.009_bib32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3727\/000000002783992352","article-title":"Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology","volume":"10","author":"Xiang","year":"2002","journal-title":"Gene Expr."},{"key":"10.1016\/j.nbd.2010.02.009_bib33","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1523\/JNEUROSCI.23-20-07504.2003","article-title":"Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease","volume":"23","author":"Yan","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2010.02.009_bib35","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ana.20558","article-title":"Elevation of 12\/15 lipoxygenase products in AD and mild cognitive impairment","volume":"58","author":"Yao","year":"2005","journal-title":"Ann. Neurol."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996110000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996110000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T14:30:38Z","timestamp":1558881038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996110000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0969996110000562"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2010.02.009","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}